Arcturus Therapeutics Holdings (ARCT) Operating Income (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) posted Operating Income of -$28.9 million for Q1 2026, up 7.59% on a QoQ basis from -$31.3 million in Q4 2025, and down 71.94% year-over-year from -$103.1 million in Q1 2025.
Arcturus Therapeutics Holdings (ARCT) Operating Income (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings' Operating Income history runs 9 years deep, the most recent figure standing at -$28.9 million for Q1 2026.
- Quarterly Operating Income fell 71.94% year-over-year to -$28.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$88.4 million (down 7.65% YoY) and the FY2025 annual result came in at -$76.3 million, up 20.29% from the prior year.
- Operating Income was -$28.9 million for Q1 2026 at Arcturus Therapeutics Holdings, up from -$31.3 million in the prior quarter.
- Across five years, Operating Income topped out at $121.5 million in Q4 2022 and bottomed at -$55.4 million in Q2 2023.
- A 5-year average of -$15.7 million and a median of -$21.1 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income jumped 422.62% — and 2024, when it slumped 306.11%.
- Arcturus Therapeutics Holdings' Operating Income stood at $121.5 million in 2022, then sank by 115.04% to -$18.3 million in 2023, then sank by 82.76% to -$33.4 million in 2024, then rose by 6.25% to -$31.3 million in 2025, then climbed by 7.59% to -$28.9 million in 2026.
- Business Quant data shows ARCT's Operating Income at -$28.9 million in Q1 2026, -$31.3 million in Q4 2025, and -$16.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Arcturus Therapeutics Holdings | 164.57 Mn | -46.81 Mn | - | -28.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.93 Mn |
| Dec 31, 2025 | -31.31 Mn |
| Sep 30, 2025 | -16.51 Mn |
| Jun 30, 2025 | -11.62 Mn |
| Mar 31, 2025 | -16.83 Mn |
| Dec 31, 2024 | -33.39 Mn |
| Sep 30, 2024 | -10.74 Mn |
| Jun 30, 2024 | -21.13 Mn |
| Mar 31, 2024 | -30.41 Mn |
| Dec 31, 2023 | -18.27 Mn |
| Sep 30, 2023 | -19.31 Mn |
| Jun 30, 2023 | -55.37 Mn |
| Mar 31, 2023 | 14.76 Mn |
| Dec 31, 2022 | 121.45 Mn |
| Sep 30, 2022 | -36.81 Mn |
| Jun 30, 2022 | -22.09 Mn |
| Mar 31, 2022 | -50.38 Mn |
| Dec 31, 2021 | -37.65 Mn |
| Sep 30, 2021 | -53.82 Mn |
| Jun 30, 2021 | -53.72 Mn |